Literature DB >> 11290401

Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia.

C Beasley1, D Cotter, N Khan, C Pollard, P Sheppard, I Varndell, S Lovestone, B Anderton, I Everall.   

Abstract

Cytoarchitectural abnormalities have been reported in the cortex in schizophrenia. These suggest a developmental origin for this disorder. The Wnt signalling pathway is involved in the regulation of brain development; disruption of this pathway may lead to abnormal cortical development. In this study levels of three components of the Wnt signalling pathway; glycogen synthase kinase-3beta(GSK-3beta), beta-catenin and dishevelled-2 (Dvl-2) were determined in the prefrontal cortex of ten schizophrenic and ten control individuals using immunoblotting. GSK-3beta levels were significantly reduced in the schizophrenic group, while levels of beta-catenin and Dvl-2 did not differ between groups. This provides further evidence for an abnormality of the Wnt signalling pathway in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290401     DOI: 10.1016/s0304-3940(01)01688-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  30 in total

Review 1.  Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.

Authors:  B Dean
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

2.  Adult neurogenesis and neurodegenerative diseases: A systems biology perspective.

Authors:  Emrin Horgusluoglu; Kelly Nudelman; Kwangsik Nho; Andrew J Saykin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-02-16       Impact factor: 3.568

Review 3.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

Review 4.  The role of GSK-3 in synaptic plasticity.

Authors:  S Peineau; C Bradley; C Taghibiglou; A Doherty; Z A Bortolotto; Y T Wang; G L Collingridge
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 5.  Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.

Authors:  Fabio Fumagalli; Angelisa Frasca; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide.

Authors:  Ghanshyam N Pandey; Yogesh Dwivedi; Hooriyah S Rizavi; Tara Teppen; Gabor L Gaszner; Rosalinda C Roberts; Robert R Conley
Journal:  Neurochem Res       Date:  2008-06-28       Impact factor: 3.996

Review 7.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

8.  Region-specific dysregulation of glycogen synthase kinase-3β and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Madhulika Tripathi; Xinguo Ren
Journal:  Bipolar Disord       Date:  2014-07-08       Impact factor: 6.744

9.  α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.

Authors:  Jessica Deslauriers; Christian Desmarais; Philippe Sarret; Sylvain Grignon
Journal:  J Mol Neurosci       Date:  2012-09-14       Impact factor: 3.444

10.  A genome-wide association study of neuroticism in a population-based sample.

Authors:  Federico C F Calboli; Federica Tozzi; Nicholas W Galwey; Athos Antoniades; Vincent Mooser; Martin Preisig; Peter Vollenweider; Dawn Waterworth; Gerard Waeber; Michael R Johnson; Pierandrea Muglia; David J Balding
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.